Frontlight ResearchEarly access
Taking people in United StatesNo phase
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
Key facts
- Who runs it
- Innoviva Specialty Therapeutics
- Where
- Akron, Cincinnati, Gainesville, Greenville, Kansas City, Lexington, New Orleans, Pittsburgh, Sacramento, Shreveport, Tampa, and The Bronx, United StatesSee the 12 sites
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 28 Apr 2025
- Expected to end
- 31 Jan 2029
- Type of study
- Observational
- Record updated
- 24 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participant is ≥18 years old at the time of written informed consent and is hospitalized
- Participant has provided the written informed consent. If a participant is unable to provide written informed consent due to their medical condition, the participant's legally authorized representative may consent on behalf of the participant, or the decision can be made according to the procedure permitted by local law and institutional standard operating procedures (SOPs)
- Participant has a proven or strongly suspected diagnosis of an infection caused by susceptible ABC isolates, based on investigator's clinical judgment
- Participant initiates treatment with SUL-DUR per routine clinical care. Participants who receive SUL-DUR within 24 hours prior to enrollment are also eligible to participate. The decision to treat the participant with SUL-DUR is made prior to and independently of study participation
- The participant has an expected survival of >48 hours at the time of written informed consent
Who cannot take part
- A history of significant hypersensitivity or allergic reaction to any β-lactam, or any contraindication to the use of β-lactam antibiotics
Where in United States
- Summa Health System - Akron - 75 Arch StreetAkron, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- The Carl and Edyth Lindner Center for Research and Education at Christ HospitalCincinnati, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- University of Florida - GainesvilleGainesville, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- Prisma Health - Infectious Diseases - GreenvilleGreenville, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- University of Kansas Medical Center-Kansas City-3901 Rainbow BlvdKansas City, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- University of Kentucky College of MedicineLexington, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- Ochsner Medical Center - New OrleansNew Orleans, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- University of Pittsburg School of MedicinePittsburgh, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- UC Davis HealthSacramento, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- Ochsner LSU Health Science Center ShreveportShreveport, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- Tampa General HospitalTampa, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
- Montefiore Medical Group Family Care CenterThe Bronx, United StatesContact: Reddy Tummala ISTX Clinical TrialsTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in order to collect safety and reaction data.
The group in the trial
- Acinetobacter baumannii-calcoaceticus complex (ABC)
Hospitalized participants with a proven or strongly suspected ABC infection who have received sulbactam-durlobactam as standard of care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-arm, Open-label, Prospective, Observational Study to Assess the Safety of Sulbactam-durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-calcoaceticus Complex Infection
- Record updated
- 24 June 2026